| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.026 | 0.9 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |